OraSure Technologies, Inc. (OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the appointment of David J. Shulkin, M.D., as a member of the Company’s Board of Directors. Dr. Shulkin, a former Secretary of the U.S. Department of Veterans Affairs, will serve as a Class I Director with an initial term expiring at the Company’s 2022 Annual Meeting of Stockholders. “We are very pleased that David has agreed to serve on our Board of Directors,” said Stephen S. Tang, Ph.D., President and Chief Executive Officer of OraSure Technologies.
BETHLEHEM, Pa., May 06, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
2020 First Quarter Earnings Conference Call Wednesday, May 6, 2020, 5:00 p.m. ET BETHLEHEM, Pa., April 09, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR) has.
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OTTAWA, May 04, 2020 -- DNA Genotek Inc., a leading provider of sample collection kits and end-to-end services and a wholly-owned subsidiary of OraSure Technologies, Inc..
The Bethlehem company received federal funding for the project from Biomedical Advanced Research and Development Authority.
OraSure Technologies (OSUR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Lisa Nibauer has been appointed Executive Vice President, Business Unit Leader, Infectious Disease. Mr. Zezzo has agreed to work with Ms. Nibauer to ensure smooth and successful transition of duties, while maintaining his current pivotal role in OraSure’s COVID-19 activities.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
BETHLEHEM, Pa., May 15, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr..
OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), to develop a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples. This support from BARDA will enable OraSure to file for FDA Emergency Use Authorization (EUA) allowing for an in-home self-test to debut into the U.S. market.
BETHLEHEM, Pa., May 26, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory.
OraSure Technologies (NASDAQ:OSUR) shares have had a really impressive month, gaining 33%, after some slippage. But...
BETHLEHEM, Pa., May 14, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2020 Annual Meeting of Stockholders will be a completely virtual meeting,.
Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (OSUR), and Nom Nom™, a direct-to-consumer pet health brand, today announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services. Diversigen will also serve as Nom Nom’s central lab for the generation of high quality microbiome data.
OTTAWA, May 22, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and.
OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service. The unified Diversigen operation will continue to offer the science-driven, customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome for which CoreBiome and Diversigen are known.
With us today are Dr. Stephen Tang, president and chief executive officer; and Mr. Roberto Cuca, chief financial officer. Dr. Tang and Mr. Cuca will begin with opening statements, which will be followed with a question-and-answer session. Tang, you should note that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share and other financial performance, product development, performance, shipments and markets, business plans, regulatory filings and approvals, expectations and strategies.
Q1 2020 OraSure Technologies Inc Earnings Call